Nivolumab combined with ruxolitinib: antagonism or synergy?
PE Debureaux, J Arrondeau, D Bouscary… - Annals of …, 2018 - annalsofoncology.org
2. Lipton A, Steger GG, Figueroa J et al. Extended efficacy and safety of denosumab in
breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
Clin Cancer Res 2008; 14 (20): 6690–6696. 3. Lipton A, Steger GG, Figueroa J et al.
Randomized active-controlled phase II study of denosumab efficacy and safety in patients
with breast cancerrelated bone metastases. J Clin Oncol 2007; 25: 4431–4437. 4. Amadori
D, Aglietta M, Alessi B et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic …
breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
Clin Cancer Res 2008; 14 (20): 6690–6696. 3. Lipton A, Steger GG, Figueroa J et al.
Randomized active-controlled phase II study of denosumab efficacy and safety in patients
with breast cancerrelated bone metastases. J Clin Oncol 2007; 25: 4431–4437. 4. Amadori
D, Aglietta M, Alessi B et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic …